Care Property Invest reports FY25 in line with its 3Q25 guidance. In line with previous quarters there was a negative leasing spread (-1.08%), but the EPRA cost ratio further improved to 15.6% (+110bps). The FY26 outlook of € 1.07 EPRA EPS is below our expectations (€ 1.09) and below the € 1.11 consensus estimates. The difference is driven by the Apricusa bankruptcy announced early January (- € 0.02 EPRA EPS impact), lower than expected indexation forecasts (i.e. 1.3% for BE) and rent cuts for B...
Recently, the AvH stock rose above our €272 target (set 1 year ago), and for good reasons. FY25 results exceeded expectations, with core participations delivering record contributions overall. Entering 2026, we have updated our valuation model for the private banking segment. Recent financials and a noticeable compression in forward peer multiples have led to modestly lower current valuations and a more material reduction in our forward (FY26E) target valuations. Based on our forecasts of €294m ...
Pharvaris presented multiple datasets for deucrictibant in HAE patients in both the on-demand and prophylactic settings at the AAAAI conference. While acknowledging the usual caveats of cross-trial comparison, we believe the data gives deucrictibant a slight edge over Ekterly in the on-demand setting, where a larger proportion of deucrictibant-treated patients achieved onset of symptom relief within 12 hours (90% vs. 76% with Ekterly). In the phase 2 OLE in the prophylactic setting, long term ou...
Syensqo appoints Heike van de Kerkhof as Chair of the Board of Directors Regulated information Syensqo appoints Heike van de Kerkhof as Chair of the Board of Directors Brussels, Belgium – March 3, 2026 - 07:30 CET SYENSQO SA (“Syensqo” or “the Company”) today announces the appointment of Heike van de Kerkhof as independent Chair of its Board of Directors (“Board”), effective March 3, 2026, marking a new step in the Group’s Governance journey. She will succeed Rosemary Thorne, who will step down as chair with immediate effect and from her position as independent director on March 31, 20...
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE attacksFinal CHAPTER-1 data provide further evidence on long-term safety and efficacy of deucrictibant for the prevention of HAE attack...
Syensqo negatively surprised the market last week with weaker than expected 4Q results and with a FY26 underlying EBITDA guidance of c. € 1.1bn, which was c. 15% below our and consensus forecasts and represents a c. 7% drop vs 2025 actuals. While part of the earnings pressure in recent years relates to a more difficult macro-economic environment, a number of businesses has seen a more intense competition and also pricing pressure, including in the recently divested Oil & Gas, Aroma Performance a...
Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative
Syensqo exercises the make-whole option to early redeem €500 million senior Bonds Regulated information Syensqo exercises the make-whole option to early redeem €500 million senior Bonds Brussels, February 27, 2026 - 8:30 CET Syensqo SA (the “Issuer”) today announced its decision to exercise its make-whole redemption option to redeem its Euro 500,000,000 2.750 per cent. Fixed Rate Bonds due December 2, 2027 (ISIN: BE6282460615), following notification to the Agent and the Calculation Agent, the National Bank of Belgium, and the Luxembourg Stock Exchange, where the bonds are listed. The...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.